205 related articles for article (PubMed ID: 31039485)
1. Characterization of the first induced pluripotent stem cell line generated from a patient with autosomal dominant catecholaminergic polymorphic ventricular tachycardia due to a heterozygous mutation in cardiac calsequestrin-2.
Ross S; Holliday M; Lim S; Semsarian C
Stem Cell Res; 2019 May; 37():101450. PubMed ID: 31039485
[TBL] [Abstract][Full Text] [Related]
2. A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia.
Gray B; Bagnall RD; Lam L; Ingles J; Turner C; Haan E; Davis A; Yang PC; Clancy CE; Sy RW; Semsarian C
Heart Rhythm; 2016 Aug; 13(8):1652-60. PubMed ID: 27157848
[TBL] [Abstract][Full Text] [Related]
3. Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations.
Novak A; Barad L; Lorber A; Gherghiceanu M; Reiter I; Eisen B; Eldor L; Itskovitz-Eldor J; Eldar M; Arad M; Binah O
J Cell Mol Med; 2015 Aug; 19(8):2006-18. PubMed ID: 26153920
[TBL] [Abstract][Full Text] [Related]
4. Compound heterozygous CASQ2 mutations and long-term course of catecholaminergic polymorphic ventricular tachycardia.
Josephs K; Patel K; Janson CM; Montagna C; McDonald TV
Mol Genet Genomic Med; 2017 Nov; 5(6):788-794. PubMed ID: 29178653
[TBL] [Abstract][Full Text] [Related]
5. Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimulation.
Novak A; Barad L; Zeevi-Levin N; Shick R; Shtrichman R; Lorber A; Itskovitz-Eldor J; Binah O
J Cell Mol Med; 2012 Mar; 16(3):468-82. PubMed ID: 22050625
[TBL] [Abstract][Full Text] [Related]
6. An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of
Ng K; Titus EW; Lieve KV; Roston TM; Mazzanti A; Deiter FH; Denjoy I; Ingles J; Till J; Robyns T; Connors SP; Steinberg C; Abrams DJ; Pang B; Scheinman MM; Bos JM; Duffett SA; van der Werf C; Maltret A; Green MS; Rutberg J; Balaji S; Cadrin-Tourigny J; Orland KM; Knight LM; Brateng C; Wu J; Tang AS; Skanes AC; Manlucu J; Healey JS; January CT; Krahn AD; Collins KK; Maginot KR; Fischbach P; Etheridge SP; Eckhardt LL; Hamilton RM; Ackerman MJ; Noguer FRI; Semsarian C; Jura N; Leenhardt A; Gollob MH; Priori SG; Sanatani S; Wilde AAM; Deo RC; Roberts JD
Circulation; 2020 Sep; 142(10):932-947. PubMed ID: 32693635
[TBL] [Abstract][Full Text] [Related]
7. CASQ2 variants in Chinese children with catecholaminergic polymorphic ventricular tachycardia.
Li Q; Guo R; Gao L; Cui L; Zhao Z; Yu X; Yuan Y; Xu X
Mol Genet Genomic Med; 2019 Nov; 7(11):e949. PubMed ID: 31482657
[TBL] [Abstract][Full Text] [Related]
8. Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia.
Lodola F; Morone D; Denegri M; Bongianino R; Nakahama H; Rutigliano L; Gosetti R; Rizzo G; Vollero A; Buonocore M; Napolitano C; Condorelli G; Priori SG; Di Pasquale E
Cell Death Dis; 2016 Oct; 7(10):e2393. PubMed ID: 27711080
[TBL] [Abstract][Full Text] [Related]
9. Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations.
Kujala K; Paavola J; Lahti A; Larsson K; Pekkanen-Mattila M; Viitasalo M; Lahtinen AM; Toivonen L; Kontula K; Swan H; Laine M; Silvennoinen O; Aalto-Setälä K
PLoS One; 2012; 7(9):e44660. PubMed ID: 22962621
[TBL] [Abstract][Full Text] [Related]
10. Calsequestrin mutations and catecholaminergic polymorphic ventricular tachycardia.
Faggioni M; Kryshtal DO; Knollmann BC
Pediatr Cardiol; 2012 Aug; 33(6):959-67. PubMed ID: 22421959
[TBL] [Abstract][Full Text] [Related]
11. Patient-Specific Drug Screening Using a Human Induced Pluripotent Stem Cell Model of Catecholaminergic Polymorphic Ventricular Tachycardia Type 2.
Maizels L; Huber I; Arbel G; Tijsen AJ; Gepstein A; Khoury A; Gepstein L
Circ Arrhythm Electrophysiol; 2017 Jun; 10(6):. PubMed ID: 28630169
[TBL] [Abstract][Full Text] [Related]
12. Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia.
Sasaki K; Makiyama T; Yoshida Y; Wuriyanghai Y; Kamakura T; Nishiuchi S; Hayano M; Harita T; Yamamoto Y; Kohjitani H; Hirose S; Chen J; Kawamura M; Ohno S; Itoh H; Takeuchi A; Matsuoka S; Miura M; Sumitomo N; Horie M; Yamanaka S; Kimura T
PLoS One; 2016; 11(10):e0164795. PubMed ID: 27764147
[TBL] [Abstract][Full Text] [Related]
13. The phenotype of a CASQ2 mutation in a Saudi family with catecholaminergic polymorphic ventricular tachycardia.
Al-Hassnan ZN; Tulbah S; Al-Manea W; Al-Fayyadh M
Pacing Clin Electrophysiol; 2013 May; 36(5):e140-2. PubMed ID: 22650415
[TBL] [Abstract][Full Text] [Related]
14. Generation of two induced pluripotent stem cell lines from catecholaminergic polymorphic ventricular tachycardia patients carrying RYR2 mutations.
Kong X; Belbachir N; Zeng W; Yan CD; Navada S; Perez MV; Wu JC
Stem Cell Res; 2023 Jun; 69():103111. PubMed ID: 37210947
[TBL] [Abstract][Full Text] [Related]
15. A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.
Preininger MK; Jha R; Maxwell JT; Wu Q; Singh M; Wang B; Dalal A; Mceachin ZT; Rossoll W; Hales CM; Fischbach PS; Wagner MB; Xu C
Dis Model Mech; 2016 Sep; 9(9):927-39. PubMed ID: 27491078
[TBL] [Abstract][Full Text] [Related]
16. Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia.
di Barletta MR; Viatchenko-Karpinski S; Nori A; Memmi M; Terentyev D; Turcato F; Valle G; Rizzi N; Napolitano C; Gyorke S; Volpe P; Priori SG
Circulation; 2006 Sep; 114(10):1012-9. PubMed ID: 16908766
[TBL] [Abstract][Full Text] [Related]
17. Impaired Dynamic Sarcoplasmic Reticulum Ca Buffering in Autosomal Dominant CPVT2.
Wleklinski MJ; Kryshtal DO; Kim K; Parikh SS; Blackwell DJ; Marty I; Iyer VR; Knollmann BC
Circ Res; 2022 Sep; 131(8):673-686. PubMed ID: 36102198
[TBL] [Abstract][Full Text] [Related]
18. Catecholaminergic polymorphic ventricular tachycardia: recent mechanistic insights.
Kontula K; Laitinen PJ; Lehtonen A; Toivonen L; Viitasalo M; Swan H
Cardiovasc Res; 2005 Aug; 67(3):379-87. PubMed ID: 15913575
[TBL] [Abstract][Full Text] [Related]
19. Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyond.
Katz G; Arad M; Eldar M
Curr Probl Cardiol; 2009 Jan; 34(1):9-43. PubMed ID: 19068246
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
